RaQualia Pharma[4579]: Notice of Receipt of a One-Time Payment in Connection with the Start of a Phase II Clinical Trial for a Novel Sodium Channel Blocker, 21 October 2026 (Timely Disclosure): Nikkei Company Information DIGITAL

RaQualia Pharma announced that it received a milestone payment upon commencement of a Phase II clinical trial of a novel sodium channel blocker. The announcement was made on 21 October 2026 as a timely disclosure.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

RaQualia Pharma announced that it received a milestone payment upon commencement of a Phase II clinical trial of a novel sodium channel blocker. The announcement date was 21 October 2026.

The announcement was made as a timely disclosure, and the disclosure document did not state the specific amount. It confirmed that the Phase II clinical trial had commenced.

At a glance

As of publication dateAnnounced as a timely disclosure on 21 October 2026.

Company nameRaQualia Pharma

Nature of eventReceipt of a milestone payment upon commencement of a Phase II trial

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

The NikkeiNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.